Professional Documents
Culture Documents
DISEASE
Lauren Levy
CD is MC in whites
than in blacks and is rare in
Asian & Hispanic children
~1.4 million
Americans suffer
from IBD
Epidemiology of
Crohns disease
Prevalence:
~7 per 100,000 people;
Incidence: ~5-10 new cases
per 100,000 people/year
Bimodal distribution:
15-30yo/50-70yo
PATHOGENESIS
Multifactorial
NOD2 Polymorphisms
Acts as an intracellular receptor to
stimulate NF-kB
Chronic inflammation from T-cell activation
leading to tissue injury
After activation by Ag presentation,
unrestrained responses of Th1 cells
predominate because of defective
regulation
Th1 cytokines (IL12 & TNF-) stimulate
the inflammatory response
Type 4 HS!
Inflammatory cells recruited by these
cytokines release nonspecific inflammatory
substances (eg, arachidonic acid
metabolites, proteases, platelet activating
factor, and free radicals), which directly
injure the intestine
Growth abnormalities
GROSS
COBBLESTONE
PATHOLOGY
MUCOSA
LINEAR ULCERS
CREEPING FAT
HISTOLOG
TRANSMURAL
Y
INFLAMMATION
NON-CASEATING
GRANULOMAS
FISSURING;
LINEAR ULCERS
EXTRAINTESTINAL
MANIFESTATIONS
Skin Pyoderma gangrenosum,
erythema nodosum
Eyes Episcleritis, Uveitis
Oral ulcerations- aphthous,
stomatitis
Arthritis peripheral, spondylitis
Kidney stones MC calcium
oxalate
Gallstones
COMPLICATION
S Malabsorption/Malnutrition
Colorectal CA (Increased risk with
pancolitis)
Fistulas (can cause recurrent UTIs &
pneumaturia)
Abscesses
Strictures
More generalized pain, intermittent
colicky pain with signs of bowel
obstruction
Perianal disease
Fistula
DIFFERENTIAL DIAGNOSIS
Ulcerative colitis
Amebiasis
Appendicitis
Bacterial/Viral Gastroenteritis
Behcet disease
Celiac disease
Diverticulitis
Giardiasis
Intestinal Carcinoid tumor
Collagenous colitis
IBS
Ischemic colitis
DIAGNOSIS
Clinical Hx
Family Hx
P/E
Radiologic evaluation
Colonoscopy
Serologic testing
Stool studies:
R/O infection
Fecal calprotectin inflammatory marker
Serology: Anti-saccharomyces cerevisiae
Abs (ASCA):
Yeast abs that affect the epithelium of the
large intestine
To evaluate small
intestine (cant be
reached during
endoscopy)
Colonoscopy
Standard in the dx of CD
MRCP or ERCP
If sclerosing cholangitis is
suspected
TREATMENT
TREATMENT
Biologic agents
Infliximab (Remicade)
Anti-TNF-
Surgery
Adalimumab (Humira)
Anti-TNF-
For pts intolerant to
infliximab
Natalizumab (Tysabri)
Inhibits 4-integrin (WBC
adhesion)
Certolizumab (Cimzia)
Anti-TNF- + polyethylene
glycol
Indications:
REFERENCES
Overview of the management of Crohn disease in children and
adolescents. Athos Bousvaros, MD. UpToDate. Last Updated: May 29,
2016. http://
www.uptodate.com.auamed.idm.oclc.org/contents/overview-of-the-manag
ement-of-crohn-disease-in-children-and-adolescents?source=search_re
sult&search=crohns+disease+in+childhood&selectedTitle=1~150
Clinical manifestations of Crohn disease in children and adolescents.
Athos Bousvaros, MD; Mala Setty, MD; George H Russell, MD, MS.
UpToDate. Last Updated: May 25, 2015. http://
www.uptodate.com.auamed.idm.oclc.org/contents/clinical-manifestation
s-of-crohn-disease-in-children-and-adolescents?source=search_result&
search=crohns+disease+in+childhood&selectedTitle=2~150
Patient information: Crohn disease in children (The Basics). UpToDate.
http://
www.uptodate.com.auamed.idm.oclc.org/contents/crohn-disease-in-chil
dren-the-basics?source=search_result&search=crohns+disease+in+child
hood&selectedTitle=5~150